2,000 Shares in Amgen, Inc. (NASDAQ:AMGN) Acquired by Sargent Investment Group LLC

Sargent Investment Group LLC purchased a new stake in shares of Amgen, Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,000 shares of the medical research company’s stock, valued at approximately $389,000.

A number of other hedge funds also recently made changes to their positions in the stock. UNIVEST FINANCIAL Corp boosted its stake in shares of Amgen by 1.5% in the fourth quarter. UNIVEST FINANCIAL Corp now owns 23,544 shares of the medical research company’s stock worth $4,583,000 after acquiring an additional 355 shares during the last quarter. Pensionfund DSM Netherlands purchased a new position in Amgen during the fourth quarter worth approximately $3,738,000. Congress Asset Management Co. MA lifted its position in Amgen by 0.8% during the fourth quarter. Congress Asset Management Co. MA now owns 40,627 shares of the medical research company’s stock worth $7,909,000 after buying an additional 311 shares in the last quarter. Ferguson Wellman Capital Management Inc. lifted its position in Amgen by 0.6% during the fourth quarter. Ferguson Wellman Capital Management Inc. now owns 208,173 shares of the medical research company’s stock worth $40,525,000 after buying an additional 1,253 shares in the last quarter. Finally, Consolidated Investment Group LLC lifted its position in Amgen by 7.2% during the fourth quarter. Consolidated Investment Group LLC now owns 22,434 shares of the medical research company’s stock worth $4,367,000 after buying an additional 1,500 shares in the last quarter. Institutional investors own 79.18% of the company’s stock.

In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the completion of the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 6,000 shares of company stock worth $1,144,120 in the last quarter. Company insiders own 0.27% of the company’s stock.

A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. Goldman Sachs Group reiterated a “buy” rating and set a $232.00 price objective on shares of Amgen in a research report on Thursday, January 17th. Oppenheimer set a $224.00 target price on Amgen and gave the company a “buy” rating in a research report on Sunday, January 27th. Royal Bank of Canada restated a “neutral” rating and issued a target price on shares of Amgen in a research report on Monday, January 14th. Finally, Citigroup lifted their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research report on Friday, January 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $209.11.

Shares of AMGN stock traded down $1.46 on Wednesday, hitting $178.30. The stock had a trading volume of 2,542,108 shares, compared to its average volume of 3,041,235. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The company has a market capitalization of $110.72 billion, a PE ratio of 12.38, a P/E/G ratio of 2.17 and a beta of 1.21. Amgen, Inc. has a 1 year low of $165.22 and a 1 year high of $210.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same quarter in the previous year, the business earned $2.89 EPS. Research analysts predict that Amgen, Inc. will post 13.96 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $1.45 dividend. The ex-dividend date is Thursday, May 16th. This represents a $5.80 annualized dividend and a dividend yield of 3.25%. Amgen’s dividend payout ratio is presently 40.28%.

TRADEMARK VIOLATION NOTICE: This story was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/sargent-investment-group-llc-purchases-new-position-in-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: How do buyers and sellers choose a strike price?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.